Acute and Long-term Adverse Events Associated With Checkpoint Blockade
- 1 October 2019
- journal article
- research article
- Published by Elsevier in Seminars in Oncology Nursing
- Vol. 35 (5) , 150926
Abstract
No abstract availableKeywords
This publication has 81 references indexed in Scilit:
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune DisordersJAMA Oncology, 2016
- Risk of Gastrointestinal Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-AnalysisImmunotherapy, 2015
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterJournal of Clinical Oncology, 2015
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesAnnals of Oncology, 2015
- Systematic review: colitis associated with anti‐CTLA‐4 therapyAlimentary Pharmacology & Therapeutics, 2015
- Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral CenterCancer Immunology Research, 2015
- Ocular adverse events of molecularly targeted agents approved in solid tumours: A systematic reviewEuropean Journal of Cancer, 2014
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating ImmunosurveillanceImmunity, 2013
- Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumabCancer, 2013
- Management of Immune-Related Adverse Events and Kinetics of Response With IpilimumabJournal of Clinical Oncology, 2012